NANALYSIS SCIENTIFIC CORP (NSCI.CA) Stock Fundamental Analysis
TSX-V:NSCI - TSX Venture Exchange - CA63000Y1034 - Common Stock - Currency: CAD
We assign a fundamental rating of 4 out of 10 to NSCI. NSCI was compared to 14 industry peers in the Health Care Equipment & Supplies industry. NSCI may be in some trouble as it scores bad on both profitability and health. NSCI is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
NSCI had negative earnings in the past year.
In the past year NSCI had a positive cash flow from operations.
NSCI had negative earnings in each of the past 5 years.
In the past 5 years NSCI reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -32.18%, NSCI belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
The Return On Equity of NSCI (-87.12%) is better than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.18% | ||
| ROE | -87.12% | ||
| ROIC | N/A |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NSCI has a Gross Margin of 29.18%. This is in the lower half of the industry: NSCI underperforms 64.29% of its industry peers.
In the last couple of years the Gross Margin of NSCI has declined.
The Profit Margin and Operating Margin are not available for NSCI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
2. Health
2.1 Basic Checks
NSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NSCI has more shares outstanding
NSCI has more shares outstanding than it did 5 years ago.
NSCI has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.30, we must say that NSCI is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.30, NSCI is doing good in the industry, outperforming 71.43% of the companies in the same industry.
The Debt to FCF ratio of NSCI is 6.14, which is on the high side as it means it would take NSCI, 6.14 years of fcf income to pay off all of its debts.
NSCI has a Debt to FCF ratio of 6.14. This is amongst the best in the industry. NSCI outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that NSCI is not too dependend on debt financing.
NSCI has a Debt to Equity ratio of 0.50. This is comparable to the rest of the industry: NSCI outperforms 57.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.14 | ||
| Altman-Z | -0.3 |
ROIC/WACCN/A
WACC6.09%
2.3 Liquidity
A Current Ratio of 0.86 indicates that NSCI may have some problems paying its short term obligations.
NSCI has a Current ratio (0.86) which is comparable to the rest of the industry.
NSCI has a Quick Ratio of 0.86. This is a bad value and indicates that NSCI is not financially healthy enough and could expect problems in meeting its short term obligations.
NSCI has a Quick ratio (0.59) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
NSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.55%, which is quite impressive.
The Revenue has grown by 13.37% in the past year. This is quite good.
Measured over the past years, NSCI shows a very strong growth in Revenue. The Revenue has been growing by 40.32% on average per year.
EPS 1Y (TTM)41.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)13.37%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-5.09%
3.2 Future
The Earnings Per Share is expected to grow by 34.26% on average over the next years. This is a very strong growth
NSCI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.52% yearly.
EPS Next Y100%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.26%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.52%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NSCI. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 5.82, the valuation of NSCI can be described as very cheap.
Based on the Price/Forward Earnings ratio, NSCI is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
NSCI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.61.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.82 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NSCI is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
NSCI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NSCI is cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.34 | ||
| EV/EBITDA | 25.79 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NSCI's earnings are expected to grow with 45.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.14%
EPS Next 3Y45.9%
5. Dividend
5.1 Amount
No dividends for NSCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NSCI (8/12/2025, 7:00:00 PM)
0.235
-0.01 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.93%
Ins Owner ChangeN/A
Market Cap26.98M
Analysts80
Price Target0.84 (257.45%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-98.02%
Min EPS beat(2)-98.02%
Max EPS beat(2)-98.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.47%
Min Revenue beat(2)-7.14%
Max Revenue beat(2)8.09%
Revenue beat(4)3
Avg Revenue beat(4)17.69%
Min Revenue beat(4)-7.14%
Max Revenue beat(4)53.52%
Revenue beat(8)6
Avg Revenue beat(8)17.17%
Revenue beat(12)7
Avg Revenue beat(12)3.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.16%
PT rev (3m)-21.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.17%
Revenue NY rev (1m)-3.85%
Revenue NY rev (3m)-3.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.82 | ||
| P/S | 0.6 | ||
| P/FCF | 10.34 | ||
| P/OCF | 6.03 | ||
| P/B | 1.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 25.79 |
EPS(TTM)-0.11
EYN/A
EPS(NY)0.04
Fwd EY17.19%
FCF(TTM)0.02
FCFY9.67%
OCF(TTM)0.04
OCFY16.6%
SpS0.39
BVpS0.12
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.18% | ||
| ROE | -87.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.18% | ||
| FCFM | 5.81% |
ROA(3y)-25.47%
ROA(5y)-19.28%
ROE(3y)-61.59%
ROE(5y)-43.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-24%
GM growth 5Y-17.31%
F-Score6
Asset Turnover1.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.14 | ||
| Debt/EBITDA | 4.43 | ||
| Cap/Depr | 42.5% | ||
| Cap/Sales | 4.16% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 280.93% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.86 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -0.3 |
F-Score6
WACC6.09%
ROIC/WACCN/A
Cap/Depr(3y)97.82%
Cap/Depr(5y)114.88%
Cap/Sales(3y)16.41%
Cap/Sales(5y)20.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y100%
EPS Next 2Y65.14%
EPS Next 3Y45.9%
EPS Next 5Y34.26%
Revenue 1Y (TTM)13.37%
Revenue growth 3Y41.54%
Revenue growth 5Y40.32%
Sales Q2Q%-5.09%
Revenue Next Year-0.13%
Revenue Next 2Y5.27%
Revenue Next 3Y5.73%
Revenue Next 5Y5.52%
EBIT growth 1Y81.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year253.78%
EBIT Next 3Y72.2%
EBIT Next 5Y52.3%
FCF growth 1Y114.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y139.78%
OCF growth 3YN/A
OCF growth 5Y33.1%